{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:11:07Z","timestamp":1767150667738,"version":"build-2238731810"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vacunas"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vacun.2022.02.002","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T16:40:25Z","timestamp":1651509625000},"page":"68-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S1","title":["Reporte de caso de s\u00edndrome de Guillain-Barr\u00e9 posterior a la vacuna COVID BNT162b2 mRNA"],"prefix":"10.1016","volume":"23","author":[{"given":"Oscar","family":"Sosa-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sof\u00eda","family":"S\u00e1nchez-Cardoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vacun.2022.02.002_bb0005","doi-asserted-by":"crossref","first-page":"e243629","DOI":"10.1136\/bcr-2021-243629","article-title":"Case of Guillain-Barr\u00e9 syndrome following COVID-19 vaccine","volume":"14","author":"Hasan","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"26","key":"10.1016\/j.vacun.2022.02.002_bb0010","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1056\/NEJMc2009191","article-title":"Guillain-Barr\u00e9 syndrome associated with SARS-CoV-2","volume":"382","author":"Toscano","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vacun.2022.02.002_bb0015","first-page":"1","article-title":"Guillain-Barr\u00e9 syndrome following BNT162b2 COVID-19 vaccine","author":"Trimboli","year":"2021","journal-title":"Neurol Sci"},{"issue":"4","key":"10.1016\/j.vacun.2022.02.002_bb0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neurop.2021.09.002","article-title":"Guillain-Barre syndrome after vaccination for Covid-19. The first report in Latin America","volume":"1","author":"Arce G\u00e1lvez","year":"2021","journal-title":"Neurol Perspect"},{"key":"10.1016\/j.vacun.2022.02.002_bb0025","doi-asserted-by":"crossref","first-page":"108786","DOI":"10.1016\/j.clim.2021.108786","article-title":"Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study","volume":"229","author":"Garc\u00eda-Grimshaw","year":"2021","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vacun.2022.02.002_bb0030","doi-asserted-by":"crossref","first-page":"108818","DOI":"10.1016\/j.clim.2021.108818","article-title":"Guillain-Barr\u00e9 syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine","volume":"230","author":"Garc\u00eda-Grimshaw","year":"2021","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.vacun.2022.02.002_bb0035","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ana.26143","article-title":"Guillain-Barr\u00e9 Syndrome following ChAdOx1-S\/nCoV-19 Vaccine","volume":"90","author":"Maramattom","year":"2021","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.vacun.2022.02.002_bb0040","doi-asserted-by":"crossref","first-page":"e243629","DOI":"10.1136\/bcr-2021-243629","article-title":"Case of Guillain-Barr\u00e9 syndrome following COVID-19 vaccine","volume":"14","author":"Hasan","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"12","key":"10.1016\/j.vacun.2022.02.002_bb0045","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3201\/eid2712.211634","article-title":"Guillain-Barr\u00e9 Syndrome associated with COVID-19 vaccination","volume":"27","author":"Shao","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vacun.2022.02.002_bb0050","author":"de M\u00e9xico"}],"updated-by":[{"DOI":"10.1016\/j.vacun.2023.09.003","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000}}],"container-title":["Vacunas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1576988722000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1576988722000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:37:19Z","timestamp":1761622639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1576988722000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":10,"alternative-id":["S1576988722000292"],"URL":"https:\/\/doi.org\/10.1016\/j.vacun.2022.02.002","relation":{},"ISSN":["1576-9887"],"issn-type":[{"value":"1576-9887","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reporte de caso de s\u00edndrome de Guillain-Barr\u00e9 posterior a la vacuna COVID BNT162b2 mRNA","name":"articletitle","label":"Article Title"},{"value":"Vacunas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vacun.2022.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}